| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 63 | 2023 | 193 | 11.320 |
Why?
|
| Smoking | 29 | 2024 | 483 | 3.540 |
Why?
|
| Health Promotion | 15 | 2018 | 280 | 3.030 |
Why?
|
| Smoking Prevention | 13 | 2017 | 54 | 2.560 |
Why?
|
| Internet | 20 | 2019 | 229 | 2.260 |
Why?
|
| Motivation | 16 | 2019 | 130 | 2.130 |
Why?
|
| Hotlines | 5 | 2017 | 14 | 1.880 |
Why?
|
| Oral Health | 4 | 2017 | 22 | 1.780 |
Why?
|
| Tobacco Use Disorder | 14 | 2016 | 49 | 1.640 |
Why?
|
| Counseling | 12 | 2019 | 187 | 1.590 |
Why?
|
| Humans | 111 | 2024 | 17707 | 1.560 |
Why?
|
| Smokers | 7 | 2023 | 12 | 1.510 |
Why?
|
| Adult | 76 | 2024 | 7658 | 1.510 |
Why?
|
| Nicotine | 9 | 2023 | 50 | 1.380 |
Why?
|
| Female | 88 | 2024 | 12729 | 1.300 |
Why?
|
| Middle Aged | 69 | 2024 | 7976 | 1.270 |
Why?
|
| Male | 66 | 2024 | 10094 | 1.140 |
Why?
|
| Quinoxalines | 8 | 2014 | 12 | 1.060 |
Why?
|
| Benzazepines | 8 | 2014 | 24 | 1.050 |
Why?
|
| Hypertension | 7 | 2024 | 498 | 1.010 |
Why?
|
| Nicotinic Agonists | 11 | 2011 | 26 | 0.980 |
Why?
|
| HIV Infections | 6 | 2024 | 704 | 0.910 |
Why?
|
| Telemedicine | 2 | 2023 | 185 | 0.870 |
Why?
|
| Patient Education as Topic | 11 | 2014 | 212 | 0.870 |
Why?
|
| Mobile Applications | 1 | 2023 | 17 | 0.830 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2024 | 327 | 0.780 |
Why?
|
| Bupropion | 4 | 2009 | 12 | 0.780 |
Why?
|
| Treatment Outcome | 20 | 2020 | 1254 | 0.780 |
Why?
|
| Research Design | 2 | 2014 | 372 | 0.730 |
Why?
|
| Depression | 5 | 2020 | 504 | 0.720 |
Why?
|
| Alcohol Drinking | 8 | 2024 | 361 | 0.720 |
Why?
|
| Health Behavior | 9 | 2024 | 360 | 0.710 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 596 | 0.680 |
Why?
|
| Aged | 35 | 2024 | 6150 | 0.660 |
Why?
|
| Health Knowledge, Attitudes, Practice | 12 | 2024 | 381 | 0.660 |
Why?
|
| Tobacco Use Cessation | 2 | 2021 | 22 | 0.620 |
Why?
|
| Patient Selection | 5 | 2009 | 190 | 0.600 |
Why?
|
| Attitude to Health | 5 | 2017 | 159 | 0.600 |
Why?
|
| Mental Disorders | 4 | 2018 | 276 | 0.590 |
Why?
|
| Anxiety | 5 | 2020 | 152 | 0.580 |
Why?
|
| Tamoxifen | 8 | 2013 | 56 | 0.570 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2018 | 74 | 0.560 |
Why?
|
| Affect | 6 | 2017 | 25 | 0.550 |
Why?
|
| Feasibility Studies | 5 | 2023 | 111 | 0.550 |
Why?
|
| Insurance Coverage | 1 | 2018 | 105 | 0.550 |
Why?
|
| Insurance, Health | 1 | 2018 | 175 | 0.520 |
Why?
|
| Decision Support Techniques | 6 | 2013 | 88 | 0.520 |
Why?
|
| Breast Neoplasms | 9 | 2013 | 956 | 0.490 |
Why?
|
| Directive Counseling | 3 | 2010 | 25 | 0.480 |
Why?
|
| Blood Pressure | 7 | 2024 | 300 | 0.460 |
Why?
|
| Risk Factors | 17 | 2024 | 3367 | 0.460 |
Why?
|
| Feeding Behavior | 4 | 2010 | 166 | 0.460 |
Why?
|
| Community-Institutional Relations | 1 | 2013 | 42 | 0.430 |
Why?
|
| Risk Assessment | 10 | 2013 | 1106 | 0.430 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1218 | 0.420 |
Why?
|
| Telephone | 8 | 2015 | 161 | 0.420 |
Why?
|
| Pilot Projects | 4 | 2023 | 215 | 0.410 |
Why?
|
| Tobacco Use | 2 | 2024 | 15 | 0.410 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 15 | 0.400 |
Why?
|
| Program Evaluation | 7 | 2018 | 222 | 0.400 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 5 | 2024 | 52 | 0.400 |
Why?
|
| Mood Disorders | 3 | 2019 | 18 | 0.390 |
Why?
|
| Behavior Therapy | 3 | 2018 | 144 | 0.390 |
Why?
|
| Chlamydia Infections | 3 | 2006 | 22 | 0.390 |
Why?
|
| Needs Assessment | 1 | 2012 | 69 | 0.380 |
Why?
|
| Biomarkers | 2 | 2004 | 312 | 0.370 |
Why?
|
| Self Care | 4 | 2017 | 164 | 0.360 |
Why?
|
| Pandemics | 3 | 2021 | 286 | 0.350 |
Why?
|
| Washington | 9 | 2020 | 382 | 0.350 |
Why?
|
| Online Systems | 2 | 2008 | 8 | 0.340 |
Why?
|
| Spirometry | 1 | 2010 | 65 | 0.340 |
Why?
|
| Patient Compliance | 3 | 2018 | 299 | 0.340 |
Why?
|
| Asthma | 4 | 2017 | 385 | 0.340 |
Why?
|
| Sick Role | 2 | 2002 | 9 | 0.320 |
Why?
|
| Adolescent | 11 | 2018 | 3671 | 0.320 |
Why?
|
| Feedback | 3 | 2019 | 19 | 0.320 |
Why?
|
| Socioeconomic Factors | 5 | 2018 | 626 | 0.320 |
Why?
|
| Varenicline | 8 | 2014 | 13 | 0.300 |
Why?
|
| Therapy, Computer-Assisted | 4 | 2019 | 10 | 0.300 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2013 | 11 | 0.290 |
Why?
|
| Diet | 2 | 2014 | 367 | 0.290 |
Why?
|
| Mass Screening | 4 | 2015 | 667 | 0.280 |
Why?
|
| Young Adult | 9 | 2019 | 2450 | 0.270 |
Why?
|
| Depressive Disorder | 1 | 2009 | 220 | 0.270 |
Why?
|
| Combined Modality Therapy | 5 | 2010 | 146 | 0.270 |
Why?
|
| Qualitative Research | 2 | 2024 | 257 | 0.260 |
Why?
|
| Bipolar Disorder | 2 | 2018 | 59 | 0.260 |
Why?
|
| Exercise | 1 | 2011 | 496 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2016 | 379 | 0.250 |
Why?
|
| Patient Portals | 2 | 2017 | 24 | 0.250 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2005 | 8 | 0.250 |
Why?
|
| Cues | 2 | 2016 | 10 | 0.240 |
Why?
|
| United States | 9 | 2024 | 3914 | 0.240 |
Why?
|
| Patient Participation | 1 | 2006 | 132 | 0.240 |
Why?
|
| Reminder Systems | 2 | 2017 | 80 | 0.240 |
Why?
|
| Dental Care | 2 | 2017 | 19 | 0.240 |
Why?
|
| Interviews as Topic | 5 | 2024 | 301 | 0.230 |
Why?
|
| Genetic Variation | 2 | 2015 | 81 | 0.230 |
Why?
|
| Electronic Mail | 4 | 2014 | 51 | 0.230 |
Why?
|
| Feedback, Psychological | 1 | 2004 | 5 | 0.230 |
Why?
|
| Social Support | 6 | 2017 | 204 | 0.220 |
Why?
|
| HIV Seropositivity | 2 | 2002 | 31 | 0.220 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 125 | 0.220 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2013 | 12 | 0.220 |
Why?
|
| Behavior, Addictive | 2 | 2014 | 12 | 0.210 |
Why?
|
| Computers, Handheld | 3 | 2014 | 11 | 0.210 |
Why?
|
| Time Factors | 5 | 2019 | 1095 | 0.210 |
Why?
|
| Insurance, Dental | 2 | 2013 | 12 | 0.210 |
Why?
|
| Veterans | 1 | 2024 | 137 | 0.200 |
Why?
|
| Health Maintenance Organizations | 3 | 2009 | 414 | 0.200 |
Why?
|
| Receptors, Nicotinic | 3 | 2011 | 9 | 0.200 |
Why?
|
| Antihypertensive Agents | 3 | 2024 | 159 | 0.200 |
Why?
|
| Fruit | 4 | 2010 | 79 | 0.200 |
Why?
|
| Vegetables | 4 | 2010 | 87 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 377 | 0.200 |
Why?
|
| Disease Transmission, Infectious | 1 | 2002 | 13 | 0.190 |
Why?
|
| Decision Making | 6 | 2013 | 182 | 0.190 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 13 | 0.190 |
Why?
|
| Patient Identification Systems | 1 | 2002 | 4 | 0.190 |
Why?
|
| Physicians, Primary Care | 1 | 2023 | 71 | 0.190 |
Why?
|
| Myocardial Infarction | 1 | 2024 | 234 | 0.190 |
Why?
|
| Risk Reduction Behavior | 1 | 2002 | 108 | 0.190 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 203 | 0.190 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2002 | 102 | 0.190 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2002 | 83 | 0.190 |
Why?
|
| Environmental Exposure | 1 | 2002 | 117 | 0.180 |
Why?
|
| User-Computer Interface | 2 | 2013 | 26 | 0.180 |
Why?
|
| Internal-External Control | 1 | 2001 | 12 | 0.180 |
Why?
|
| Goals | 1 | 2001 | 30 | 0.180 |
Why?
|
| Stroke | 1 | 2024 | 316 | 0.180 |
Why?
|
| Morbidity | 1 | 2021 | 59 | 0.180 |
Why?
|
| Poverty | 1 | 2002 | 166 | 0.180 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2009 | 4 | 0.170 |
Why?
|
| Neoplasms | 3 | 2024 | 442 | 0.170 |
Why?
|
| Self Efficacy | 2 | 2012 | 68 | 0.170 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 26 | 0.170 |
Why?
|
| Minority Groups | 1 | 2020 | 101 | 0.170 |
Why?
|
| Health Surveys | 3 | 2012 | 260 | 0.170 |
Why?
|
| Empathy | 1 | 2019 | 7 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2014 | 245 | 0.160 |
Why?
|
| Registries | 1 | 2002 | 470 | 0.160 |
Why?
|
| Carbon Monoxide | 2 | 2009 | 13 | 0.160 |
Why?
|
| Acceptance and Commitment Therapy | 2 | 2018 | 2 | 0.160 |
Why?
|
| Respiratory Function Tests | 2 | 2009 | 32 | 0.160 |
Why?
|
| Recurrence | 5 | 2017 | 189 | 0.160 |
Why?
|
| Animals | 5 | 2016 | 262 | 0.150 |
Why?
|
| Blood Pressure Determination | 3 | 2024 | 57 | 0.150 |
Why?
|
| African Americans | 1 | 2002 | 465 | 0.150 |
Why?
|
| Delayed-Action Preparations | 2 | 2008 | 6 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 755 | 0.150 |
Why?
|
| Health Personnel | 2 | 2022 | 123 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2018 | 38 | 0.140 |
Why?
|
| Postal Service | 2 | 2008 | 73 | 0.140 |
Why?
|
| Guideline Adherence | 3 | 2010 | 155 | 0.140 |
Why?
|
| Attitude to Computers | 1 | 2017 | 15 | 0.140 |
Why?
|
| Patient Care Team | 2 | 2014 | 111 | 0.140 |
Why?
|
| Health Care Reform | 1 | 1997 | 21 | 0.140 |
Why?
|
| Avoidance Learning | 1 | 2016 | 3 | 0.130 |
Why?
|
| Phobia, Social | 1 | 2016 | 2 | 0.130 |
Why?
|
| Bovine Respiratory Disease Complex | 1 | 2016 | 1 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2018 | 165 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2011 | 22 | 0.130 |
Why?
|
| Michigan | 4 | 2013 | 26 | 0.130 |
Why?
|
| Tuberculosis, Bovine | 1 | 2016 | 1 | 0.130 |
Why?
|
| Chromosomes, Mammalian | 1 | 2016 | 1 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2018 | 222 | 0.130 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 38 | 0.130 |
Why?
|
| Self Report | 4 | 2020 | 252 | 0.130 |
Why?
|
| Health Policy | 1 | 1997 | 118 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2011 | 16 | 0.130 |
Why?
|
| Alcoholism | 1 | 2019 | 332 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2015 | 1 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 483 | 0.120 |
Why?
|
| Lipids | 1 | 2015 | 82 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 3 | 2008 | 243 | 0.120 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 33 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 249 | 0.120 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2014 | 3 | 0.120 |
Why?
|
| Nausea | 2 | 2011 | 8 | 0.110 |
Why?
|
| Communication | 1 | 2015 | 191 | 0.110 |
Why?
|
| Oregon | 3 | 2009 | 187 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2024 | 970 | 0.110 |
Why?
|
| Financing, Government | 1 | 2013 | 27 | 0.110 |
Why?
|
| Disease Management | 1 | 2014 | 136 | 0.110 |
Why?
|
| Program Development | 1 | 2013 | 68 | 0.110 |
Why?
|
| Logistic Models | 4 | 2009 | 918 | 0.110 |
Why?
|
| Horse Diseases | 1 | 2013 | 1 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 90 | 0.100 |
Why?
|
| Premedication | 1 | 2013 | 2 | 0.100 |
Why?
|
| Communicable Disease Control | 1 | 2013 | 18 | 0.100 |
Why?
|
| Informed Consent | 1 | 2013 | 20 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 46 | 0.100 |
Why?
|
| Adaptation, Psychological | 3 | 2021 | 79 | 0.100 |
Why?
|
| Sex Characteristics | 4 | 2009 | 69 | 0.100 |
Why?
|
| Cholesterol | 1 | 2012 | 106 | 0.100 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1322 | 0.090 |
Why?
|
| Genotype | 4 | 2016 | 227 | 0.090 |
Why?
|
| Telecommunications | 1 | 2011 | 1 | 0.090 |
Why?
|
| Mothers | 3 | 2017 | 106 | 0.090 |
Why?
|
| Community Participation | 1 | 2010 | 29 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 1927 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 177 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2010 | 41 | 0.090 |
Why?
|
| Alleles | 3 | 2016 | 85 | 0.080 |
Why?
|
| Comprehension | 1 | 2009 | 17 | 0.080 |
Why?
|
| Saliva | 1 | 2009 | 12 | 0.080 |
Why?
|
| Consumer Health Information | 1 | 2009 | 14 | 0.080 |
Why?
|
| DNA | 1 | 2009 | 22 | 0.080 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 10 | 0.080 |
Why?
|
| Nicotinic Antagonists | 1 | 2009 | 1 | 0.080 |
Why?
|
| Nutrition Therapy | 1 | 2009 | 4 | 0.080 |
Why?
|
| Women's Health | 2 | 2013 | 199 | 0.080 |
Why?
|
| Specimen Handling | 1 | 2009 | 20 | 0.080 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 26 | 0.080 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Comorbidity | 3 | 2017 | 590 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 4 | 0.080 |
Why?
|
| Psychology | 1 | 2009 | 16 | 0.080 |
Why?
|
| Audiovisual Aids | 1 | 2008 | 3 | 0.080 |
Why?
|
| Diet Surveys | 1 | 2009 | 57 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2017 | 416 | 0.080 |
Why?
|
| European Continental Ancestry Group | 3 | 2010 | 523 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2008 | 43 | 0.080 |
Why?
|
| Prognosis | 2 | 2008 | 613 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2009 | 248 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2012 | 694 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 85 | 0.070 |
Why?
|
| Correspondence as Topic | 1 | 2006 | 4 | 0.070 |
Why?
|
| Group Practice, Prepaid | 1 | 2006 | 6 | 0.070 |
Why?
|
| Chlamydia trachomatis | 1 | 2006 | 6 | 0.070 |
Why?
|
| Ireland | 2 | 2016 | 3 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2006 | 14 | 0.070 |
Why?
|
| Cattle | 2 | 2016 | 6 | 0.070 |
Why?
|
| Women's Health Services | 1 | 2006 | 16 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 355 | 0.070 |
Why?
|
| Preventive Medicine | 1 | 2006 | 24 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 3 | 0.060 |
Why?
|
| Drug Eruptions | 1 | 2006 | 4 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2006 | 70 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 154 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2018 | 2471 | 0.060 |
Why?
|
| Child | 3 | 2017 | 2481 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2006 | 123 | 0.060 |
Why?
|
| Adolescent Behavior | 1 | 2006 | 127 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2017 | 48 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1117 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2005 | 103 | 0.060 |
Why?
|
| Problem Solving | 2 | 2002 | 10 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 1287 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2024 | 6 | 0.060 |
Why?
|
| Sex Factors | 3 | 2012 | 639 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 371 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 204 | 0.050 |
Why?
|
| Microcomputers | 1 | 2003 | 1 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 162 | 0.050 |
Why?
|
| Quality of Life | 2 | 2024 | 521 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2002 | 2 | 0.050 |
Why?
|
| Defense Mechanisms | 1 | 2002 | 1 | 0.050 |
Why?
|
| Louisiana | 1 | 2002 | 17 | 0.050 |
Why?
|
| Community Mental Health Services | 1 | 2002 | 32 | 0.050 |
Why?
|
| Life Change Events | 1 | 2002 | 31 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 46 | 0.050 |
Why?
|
| Documentation | 1 | 2002 | 42 | 0.050 |
Why?
|
| Judgment | 1 | 2001 | 3 | 0.050 |
Why?
|
| Social Isolation | 1 | 2021 | 16 | 0.050 |
Why?
|
| Achievement | 1 | 2001 | 3 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 16 | 0.050 |
Why?
|
| Pregnancy | 2 | 2004 | 1535 | 0.040 |
Why?
|
| Tobacco Products | 1 | 2021 | 17 | 0.040 |
Why?
|
| Students | 1 | 2001 | 54 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2000 | 10 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2002 | 397 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1999 | 33 | 0.040 |
Why?
|
| Saskatchewan | 1 | 2018 | 1 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 561 | 0.040 |
Why?
|
| Behavior | 1 | 1998 | 18 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2009 | 670 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 35 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 2017 | 46 | 0.030 |
Why?
|
| Emotions | 1 | 2016 | 35 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 1996 | 1 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 1996 | 1 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1996 | 6 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 1996 | 3 | 0.030 |
Why?
|
| Breeding | 1 | 2016 | 1 | 0.030 |
Why?
|
| Dairying | 1 | 2016 | 1 | 0.030 |
Why?
|
| Mycobacterium bovis | 1 | 2016 | 1 | 0.030 |
Why?
|
| United Kingdom | 1 | 2016 | 28 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 1996 | 38 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 65 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 72 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 128 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 21 | 0.030 |
Why?
|
| Self-Management | 1 | 2015 | 29 | 0.030 |
Why?
|
| Primary Health Care | 2 | 2015 | 756 | 0.030 |
Why?
|
| Organic Cation Transporter 2 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 882 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 185 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2014 | 40 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2009 | 717 | 0.030 |
Why?
|
| Craving | 1 | 2013 | 11 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 80 | 0.030 |
Why?
|
| Education, Veterinary | 1 | 2013 | 1 | 0.030 |
Why?
|
| Veterinarians | 1 | 2013 | 1 | 0.030 |
Why?
|
| Horses | 1 | 2013 | 2 | 0.030 |
Why?
|
| Bacteria | 1 | 2013 | 4 | 0.030 |
Why?
|
| Conflict (Psychology) | 1 | 2013 | 7 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 172 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 15 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2013 | 12 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2013 | 36 | 0.030 |
Why?
|
| Information Seeking Behavior | 1 | 2012 | 10 | 0.030 |
Why?
|
| Intention | 1 | 2012 | 28 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 23 | 0.020 |
Why?
|
| Weight Loss | 1 | 2014 | 305 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2013 | 265 | 0.020 |
Why?
|
| Retention (Psychology) | 1 | 2010 | 7 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 1199 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 49 | 0.020 |
Why?
|
| Menu Planning | 1 | 2009 | 2 | 0.020 |
Why?
|
| Education, Nonprofessional | 1 | 2009 | 6 | 0.020 |
Why?
|
| Mass Media | 1 | 2009 | 17 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 30 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2009 | 19 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 918 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 29 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 159 | 0.020 |
Why?
|
| Cognition | 1 | 2009 | 82 | 0.020 |
Why?
|
| Computer User Training | 1 | 2008 | 2 | 0.020 |
Why?
|
| Photography | 1 | 2008 | 10 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2010 | 227 | 0.020 |
Why?
|
| Focus Groups | 1 | 2009 | 146 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2008 | 22 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 252 | 0.020 |
Why?
|
| Perception | 1 | 2008 | 57 | 0.020 |
Why?
|
| Midwestern United States | 1 | 2008 | 3 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 237 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 296 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2009 | 301 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 314 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 2589 | 0.010 |
Why?
|
| Southeastern United States | 1 | 2002 | 9 | 0.010 |
Why?
|
| Marital Status | 1 | 2002 | 20 | 0.010 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1999 | 14 | 0.010 |
Why?
|
| Sleep Stages | 1 | 1999 | 1 | 0.010 |
Why?
|
| Hunger | 1 | 1999 | 5 | 0.010 |
Why?
|
| Polysomnography | 1 | 1999 | 5 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1999 | 160 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2000 | 99 | 0.010 |
Why?
|
| Sleep | 1 | 1999 | 58 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 63 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2000 | 129 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1996 | 6 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 100 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1997 | 140 | 0.010 |
Why?
|
| Disease Progression | 1 | 1996 | 266 | 0.010 |
Why?
|